Antagonist

Novartis Inc., has acquired the US Bio-tech Firm Spinifex Pharmaceuticals, Inc., for the total cash consideration of US$200 million plus undisclosed clinical development and regulatory milestone payments. The acquisition is centred on Spinifex’s lead candidate EMA401, a novel angiotensin II type 2 (AT2) receptor antagonist. View the full release here.